Faye M. Johnson
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston
TX 77030-4009
USA
Name/email consistency: high
- Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. Johnson, F.M., Bekele, B.N., Feng, L., Wistuba, I., Tang, X.M., Tran, H.T., Erasmus, J.J., Hwang, L.L., Takebe, N., Blumenschein, G.R., Lippman, S.M., Stewart, D.J. J. Clin. Oncol. (2010)
- Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Johnson, F.M., Agrawal, S., Burris, H., Rosen, L., Dhillon, N., Hong, D., Blackwood-Chirchir, A., Luo, F.R., Sy, O., Kaul, S., Chiappori, A.A. Cancer (2010)
- SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Johnson, F.M., Gallick, G.E. Anticancer. Agents. Med. Chem (2007)
- Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Johnson, F.M., Saigal, B., Tran, H., Donato, N.J. Clin. Cancer Res. (2007)
- Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. Johnson, F.M., Saigal, B., Donato, N.J. J. Cell. Physiol. (2005)
- Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Johnson, F.M., Saigal, B., Talpaz, M., Donato, N.J. Clin. Cancer Res. (2005)
- Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate. Johnson, F.M., Yang, P., Newman, R.A., Donato, N.J. J. Exp. Ther. Oncol. (2004)
